Advanced Enzyme

Why is Advanced Enzyme Technologies Ltd falling/rising?

As of 14-Aug, Advanced Enzyme Technologies Ltd's stock price has risen to 303.40, up 0.81%, but it has declined 6.47% over the past week and shows negative long-term performance indicators. Despite the recent increase, caution is advised due to ongoing challenges and a general downward trend.

As of 14-Aug, Advanced Enzyme Technologies Ltd is experiencing a rise in its stock price, currently at 303.40, reflecting an increase of 2.45 (0.81%). This upward movement is notable as the stock has outperformed its sector by 1.48% today. Additionally, the stock reached an intraday high of Rs 308.8, marking a 2.61% increase during the trading session.<BR><BR>However, it is important to consider the broader context of the stock's performance. Over the past week, the stock has declined by 6.47%, and it has shown a negative return of 6.44% over the past month. Despite this recent rise, the stock has been trading below its moving averages across various time frames, indicating a general downward trend. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by 62.39% compared to the 5-day average.<BR><BR>On a positive note, the company is net-debt free and has high institutional holdings at 31.49%, which have increased by 0.59% over the previous quarter. These institutional investors typically have better resources to analyze the company's fundamentals, which may contribute to some confidence in the stock.<BR><BR>Nonetheless, the long-term outlook remains concerning, with operating profit showing a negative growth rate of -2.89% over the last five years, and the stock has consistently underperformed against benchmarks over the past three years. The recent rise in stock price may be a short-term reaction rather than a reflection of improved fundamentals, as the company has faced challenges such as flat results in June and a low operating profit to net sales ratio.<BR><BR>In summary, while Advanced Enzyme Technologies Ltd is currently experiencing a rise in its stock price, the overall trend and long-term performance indicators suggest caution due to significant past declines and ongoing challenges.

Which are the latest news on Advanced Enzyme?

Who are in the management team of Advanced Enzyme?

The management team of Advanced Enzyme includes key members such as Mukund Madhusudan Kabra (Whole-time Director), Vasant Rathi (Chairman), and several independent directors including Kedar Jagdish Desai and Pramod Kasat, among others. This diverse team provides strategic direction and governance for the company.

The management team of Advanced Enzyme includes the following key members:<BR><BR>1. **Mukund Madhusudan Kabra** - Whole-time Director<BR>2. **Kedar Jagdish Desai** - Independent Director<BR>3. **Vasant Rathi** - Chairman (Non-Executive)<BR>4. **Pramod Kasat** - Independent Director<BR>5. **Sanjay Basantani** - Company Secretary & Compliance Officer<BR>6. **Rajesh Kumar Sharma** - Independent Director<BR>7. **Rasika Rathi** - Non-Executive & Non-Independent Director<BR>8. **Vindokumar Hiralal Jajoo** - Independent Director<BR>9. **Sunny Sharma** - Non-Executive & Non-Independent Director<BR>10. **Rajshree Patel** - Independent Director<BR>11. **Nitin Jagannath Deshmukh** - Independent Director<BR>12. **Vandana Tilak** - Independent Director<BR><BR>This diverse team brings a range of expertise to the company, contributing to its strategic direction and governance.

What does Advanced Enzyme do?

Advanced Enzyme Technologies Ltd is India's largest enzyme manufacturer in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 3,385 Cr and reported net sales of 190 Cr and net profit of 37 Cr for June 2026. The company has a P/E ratio of 21.00 and a dividend yield of 0.44%.

Overview:<BR>Advanced Enzyme Technologies Ltd is the largest Indian enzyme company engaged in the manufacturing and sale of enzymes, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in 1989 as 'Advanced Biochemicals Private Limited' and later underwent several name changes, becoming a Public Company in 1992 and adopting its current name in 2005. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 190 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 37 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 3,385 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 44<BR>- Dividend Yield: 0.44%<BR>- Debt Equity: -0.41<BR>- Return on Equity: 9.82%<BR>- Price to Book: 2.07<BR><BR>Contact Details:<BR>Address: Sun Magnetica 5th Floor, Nr LIC Service Road Louiswadi Thane Maharashtra : 400604<BR>Tel: 91-22-41703200<BR>Email: info@advancedenzymes.com<BR>Website: http://www.advancedenzymes.com

Who are the peers of the Advanced Enzyme?

Peers of Advanced Enzyme include Novartis India, Unichem Labs, Guj. Themis Bio, and others, with varying management risks and growth rates. Kwality Pharma leads in 1-year returns at 208.46%, while Advanced Enzyme's return is -1.78%.

Peers: The peers of Advanced Enzyme are Novartis India, Unichem Labs., Guj. Themis Bio., SMS Pharma., Kwality Pharma, Dishman Carbogen, Hikal, Ind-Swift Labs., and Panacea Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India and Guj. Themis Bio., while Average management risk is found at Unichem Labs., SMS Pharma., Kwality Pharma, Hikal, and the rest. Below Average management risk is noted at Dishman Carbogen, Ind-Swift Labs., and Panacea Biotec. Good growth is seen at Novartis India, Unichem Labs., and Kwality Pharma, while Below Average growth is present at Guj. Themis Bio., SMS Pharma., Advanced Enzyme, Hikal, and the rest. Excellent capital structure is attributed to Novartis India, Guj. Themis Bio., Advanced Enzyme, and Kwality Pharma, while Good capital structure is found at Unichem Labs. and SMS Pharma, and Average capital structure is noted at Ind-Swift Labs. and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kwality Pharma at 208.46%, while the lowest is Dishman Carbogen at -22.16%. Advanced Enzyme's 1-year return is -1.78%, which is higher than Dishman Carbogen's but lower than Kwality Pharma's. Additionally, Dishman Carbogen, Hikal, Ind-Swift Labs., and Panacea Biotec have negative six-month returns.

How big is Advanced Enzyme?

As of 14th August, Advanced Enzyme Technologies Ltd has a market capitalization of 3,404.07 Cr, with recent net sales of 749.64 Cr and net profit of 165.88 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Advanced Enzyme Technologies Ltd has a market capitalization of 3,404.07 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 749.64 Cr, while the sum of Net Profit for the same period is 165.88 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2026. Shareholder's Funds stand at 1,631.96 Cr, and Total Assets amount to 1,833.88 Cr.

Should I buy, sell or hold Advanced Enzyme Technologies Ltd?

Are Advanced Enzyme Technologies Ltd latest results good or bad?

Advanced Enzyme Technologies Ltd's latest Q4 FY26 results are strong, with a 62.24% increase in net profit and a 21.65% rise in net sales. However, concerns about low return on equity and margin consistency suggest that investors should be cautious despite the positive growth.

Advanced Enzyme Technologies Ltd's latest results for Q4 FY26 indicate a strong performance overall. The company reported a consolidated net profit of ₹42.96 crores, which represents a significant year-on-year increase of 62.24%. Additionally, net sales reached ₹203.37 crores, marking a 21.65% increase compared to the same quarter last year. This quarter also saw an improvement in operating margins, which rose to 31.09%, up from 27.28% in the previous year.<BR><BR>Despite these positive indicators, there are some concerns. The return on equity (ROE) stands at 9.93%, which is below industry standards, raising questions about capital efficiency. Furthermore, the stock has shown modest gains recently and is trading at ₹357.30, reflecting a slight decline on the day but a notable increase of 28.06% over the past year.<BR><BR>In summary, while the latest quarterly results showcase strong growth in profit and sales, the company's challenges with margin consistency and return ratios suggest that investors should remain cautious. The overall performance is good, but the underlying issues warrant careful consideration.

Is Advanced Enzyme technically bullish or bearish?

As of December 1, 2025, the technical trend for Advanced Enzyme has shifted to mildly bearish, driven by bearish MACD readings and Bollinger Bands, despite some mixed signals from daily moving averages and RSI.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven primarily by the weekly and monthly MACD readings, both indicating bearish momentum. The Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the bearish signals from the KST and the overall trend change. The RSI presents a mixed picture with no signal on the weekly and bullish on the monthly, but the lack of a clear trend in Dow Theory and OBV further supports the bearish stance. Overall, the indicators suggest a weak bearish sentiment in the current market environment for Advanced Enzyme.

How has been the historical performance of Advanced Enzyme?

Advanced Enzyme has shown consistent growth in net sales, increasing from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25, but faced rising expenditures leading to a decline in operating profit and net profit. Total assets and liabilities both grew to 1,611.15 Cr by Mar'25, while cash flow from operations remained stable despite a net cash outflow of -19 Cr.

Answer:<BR>The historical performance of Advanced Enzyme shows a consistent growth in net sales and total operating income over the years, with net sales increasing from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25. The total operating income followed a similar trend, rising from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25. However, the total expenditure has also increased, reaching 442.47 Cr in Mar'25 from 237.67 Cr in Mar'19, which has impacted the operating profit, which decreased from 240.46 Cr in Mar'21 to 227.48 Cr in Mar'25. The profit before tax showed fluctuations, peaking at 210.13 Cr in Mar'21 and slightly declining to 187.36 Cr in Mar'25. The profit after tax also experienced a decline from 151.29 Cr in Mar'21 to 133.97 Cr in Mar'25. The earnings per share (EPS) decreased from 13.06 in Mar'21 to 11.72 in Mar'25, reflecting the overall profit trend. On the balance sheet, total assets grew from 971.18 Cr in Mar'20 to 1,611.15 Cr in Mar'25, while total liabilities increased from 971.18 Cr to 1,611.15 Cr in the same period. Cash flow from operating activities remained relatively stable, with a slight increase from 140 Cr in Mar'23 to 142 Cr in Mar'25, although the net cash outflow was recorded at -19 Cr in Mar'25.<BR><BR>Breakdown:<BR>Advanced Enzyme has demonstrated a robust growth trajectory in net sales, which rose from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25, indicating a strong demand for its products. The total operating income mirrored this growth, reaching 636.91 Cr in Mar'25. Despite this growth, total expenditure also increased significantly, leading to a decline in operating profit from 240.46 Cr in Mar'21 to 227.48 Cr in Mar'25. Profit before tax fluctuated, peaking at 210.13 Cr in Mar'21 before settling at 187.36 Cr in Mar'25, while profit after tax decreased from 151.29 Cr in Mar'21 to 133.97 Cr in Mar'25. The EPS followed a similar downward trend, dropping from 13.06 to 11.72 over the same period. On the balance sheet, total assets and liabilities both grew to 1,611.15 Cr by Mar'25, reflecting the company's expanding operations. Cash flow from operating activities remained stable, although the company faced a net cash outflow of -19 Cr in Mar'25, highlighting challenges in cash management despite operational profitability.

Is Advanced Enzyme overvalued or undervalued?

As of July 30, 2020, Advanced Enzyme is considered very expensive and overvalued with a PE ratio of 25.89, despite outperforming the Sensex in the short term, while its year-to-date performance is down by 10.37%.

As of 30 July 2020, the valuation grade for Advanced Enzyme moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 25.89, an EV to EBITDA of 14.64, and a Price to Book Value of 2.39, all of which suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Advanced Enzyme's PE ratio is notably lower than Solar Industries at 123.77 and Gujarat Fluoroch at 73.59, both of which are also classified as very expensive. However, it is significantly higher than Godrej Industries, which is rated attractive with a PE of 46.63. The recent stock performance shows a 1-month return of 11.21%, outperforming the Sensex's 3.87% return, but the year-to-date performance is down by 10.37%, contrasting with the Sensex's gain of 5.62%. This mixed performance further supports the conclusion of overvaluation.

Who are the top shareholders of the Advanced Enzyme?

The top shareholders of Advanced Enzyme include promoters holding the majority of shares, with Vasant Rathi having the largest stake at 33.18%. Additionally, mutual funds own 5.36%, foreign institutional investors hold 11.9%, and individual investors collectively own 16.68%.

The top shareholders of Advanced Enzyme include the promoters, who hold the majority of the shares. Notably, Vasant Rathi is the promoter with the highest holding at 33.18%. Additionally, the company has 9 mutual fund schemes holding a combined 5.36% and 70 foreign institutional investors (FIIs) holding 11.9%. Individual investors collectively hold 16.68% of the shares. The highest public shareholder is Orbimed Asia III Mauritius Fvci Limited, which holds 0%. There are no pledged promoter holdings reported.

When is the next results date for Advanced Enzyme?

No Upcoming Board Meetings

Has Advanced Enzyme declared dividend?

Yes, Advanced Enzyme Technologies Ltd has declared a dividend of 200%, amounting to ₹4 per share, with an ex-date of May 16, 2025. The dividend yield is 1.68%, and while recent returns have been volatile, the total return over the past five years is 104.53%.

Advanced Enzyme Technologies Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4<BR>- Ex-date: May 16, 2025<BR><BR>Dividend Yield: 1.68%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.63%, the dividend return was 1.02%, resulting in a total return of -18.61%.<BR><BR>Over the past year, the price return was -15.92%, with a dividend return of 1.41%, leading to a total return of -14.51%.<BR><BR>In the 2-year period, the price return was 8.5%, the dividend return was 3.69%, culminating in a total return of 12.19%.<BR><BR>For the 3-year period, the price return stood at 1.81%, the dividend return was 5.62%, resulting in a total return of 7.43%.<BR><BR>In the last 4 years, the price return was -26.95%, while the dividend return was 3.89%, leading to a total return of -23.06%.<BR><BR>Finally, over the past 5 years, the price return was 94.86%, the dividend return was 9.67%, resulting in a total return of 104.53%.<BR><BR>Overall, Advanced Enzyme Technologies Ltd has declared a significant dividend, and while recent returns have shown volatility, the long-term performance over five years indicates a strong total return driven by both price appreciation and dividends.